Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
Ominous signs for EGFR degraders
BeOne's degrader BG-60366 appears to have been discontinued.
Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
